- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/02 - Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
Patent holdings for IPC class A61P 5/02
Total number of patents in this class: 82
10-year publication summary
|
4
|
1
|
5
|
3
|
9
|
10
|
8
|
4
|
5
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glytech, Inc. | 70 |
8 |
| Novartis AG | 11229 |
3 |
| Sandoz AG | 1410 |
2 |
| Abbvie Inc. | 1789 |
2 |
| Alchemia Limited | 3 |
2 |
| Antisense Therapeutics Ltd. | 31 |
2 |
| Camurus AB | 144 |
2 |
| Chong Kun Dang Pharmaceutical Corp. | 234 |
2 |
| Heptares Therapeutics Limited | 118 |
2 |
| Shijiazhuang Yiling Pharmaceutical Co., Ltd. | 106 |
2 |
| TOLMAR International Limited | 86 |
2 |
| The General Hospital Corporation | 4659 |
1 |
| The Trustees of the University of Pennsylvania | 4283 |
1 |
| Takeda Cambridge Limited | 20 |
1 |
| American University | 59 |
1 |
| Beijing SL Pharmaceutical Co.,Ltd. | 2 |
1 |
| The Board of Regents of the University of Oklahoma | 599 |
1 |
| Cedus, Inc. | 1 |
1 |
| Entera Bio Ltd. | 37 |
1 |
| Erasmus University Medical Center Rotterdam | 345 |
1 |
| Other owners | 44 |